Pharm-Olam International Adds Executive Director, Strategic Projects to Its Global Strategic Operations Team
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to welcome Tricia A. Bland to its management team as the Executive Director, Strategic Projects.
Ms. Bland brings over 20 years of demonstrated success in the clinical research industry, leading and implementing global development strategies and successfully managing global teams. She will be based out of Pharm-Olam’s Research Triangle Park, North Carolina office. Ms. Bland will provide executive-level leadership to both staff and sponsors, strategic relationship management, and implementation of process improvement programs aimed at increasing efficiencies and improving data quality. Prior to coming to Pharm-Olam, Ms. Bland held management roles including Vice President of Corporate Development and Vice President of Proposals and Contracts at several CROs.
“We are thrilled to have Tricia join the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). Suri added, “We continually look for ways to assist pharmaceutical, biotechnology, and device companies with innovative clinical trial solutions around the world. We know how important our team members are to study success and Tricia’s addition to our team will enable us to offer distinctive ideas to support our client’s unique needs.”
For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact email@example.com .
About Pharm-Olam International Group
Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com .
Mark Eberhardt, 713-559-7350
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
BOEHRINGER-INGELHEIM26.9.2018 10:02 | pressemeddelelse
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
SOFTATHOME26.9.2018 09:02 | pressemeddelelse
SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics
EASY-VISUAL26.9.2018 09:02 | pressemeddelelse
Easy Visual Launches App For Targeted Advertising Reach Through Smartphones
CA-TELEFLEX26.9.2018 08:07 | pressemeddelelse
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate
CA-NEOTRACT26.9.2018 08:07 | pressemeddelelse
NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care
OLIVER-WYMAN26.9.2018 08:02 | pressemeddelelse
Oliver Wyman Supports Inclusion Initiative in the Nordics
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum